{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T20:08:31Z","timestamp":1792786111265,"version":"4.5.0"},"reference-count":32,"publisher":"Oxford University Press (OUP)","issue":"3","license":[{"start":{"date-parts":[[2025,3,13]],"date-time":"2025-03-13T00:00:00Z","timestamp":1741824000000},"content-version":"vor","delay-in-days":12,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006108","name":"National Center for Advancing Translational Sciences","doi-asserted-by":"publisher","award":["KL2TR002385"],"award-info":[{"award-number":["KL2TR002385"]}],"id":[{"id":"10.13039\/100006108","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100020424","name":"Weill Cornell Medicine","doi-asserted-by":"publisher","award":["87001082"],"award-info":[{"award-number":["87001082"]}],"id":[{"id":"10.13039\/100020424","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100020424","name":"Weill Cornell Medicine","doi-asserted-by":"publisher","award":["87001319"],"award-info":[{"award-number":["87001319"]}],"id":[{"id":"10.13039\/100020424","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100020424","name":"Weill Cornell Medicine","doi-asserted-by":"publisher","award":["87000784"],"award-info":[{"award-number":["87000784"]}],"id":[{"id":"10.13039\/100020424","id-type":"DOI","asserted-by":"publisher"}]},{"name":"NIH\/NCI Cancer Center Support","award":["P30 CA008748"],"award-info":[{"award-number":["P30 CA008748"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,3,10]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Kaposi sarcoma (KS) is a vascular tumor caused by human herpesvirus 8, also known as Kaposi sarcoma herpesvirus. There are 4 distinct subtypes: classic, endemic, iatrogenic, and epidemic (HIV-associated). A fifth subtype is increasingly recognized: non-epidemic KS in men who have sex with men (MSM) who are HIV-negative. Our primary objective was to characterize non-epidemic KS to identify associated risk factors, presentation, treatment course, and prognosis of these patients.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Patients and Methods<\/jats:title>\n                    <jats:p>This retrospective cohort included all patients evaluated at Memorial Sloan Kettering Cancer Center from 2000 to 2022 with pathologically proven KS who identified as MSM status, without diagnosis of HIV. Data were collected on demographics, comorbidities, coinfections, treatments, and outcomes.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Seventy-two patients were identified. The median age at the time of diagnosis was 58. At initial diagnosis, 44% of patients underwent observation, 51% received localized treatment and 5% received systemic treatment. In follow-up, 47% of patients had a progression of disease requiring recurrent treatment: 25% received localized treatment while 18% received chemotherapy. In follow-up, 7 patients died, with only 2 deaths attributed to KS; 10% of patients were diagnosed with a lymphoproliferative disorder.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>This study is the largest yet to characterize the non-epidemic KS subtype in HIV-negative MSM. These individuals are younger, HIV-negative, MSM with a favorable prognosis. Additional research is needed to understand the potential risk associated with lymphoproliferative disorders.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/oncolo\/oyaf024","type":"journal-article","created":{"date-parts":[[2025,1,31]],"date-time":"2025-01-31T15:26:46Z","timestamp":1738337206000},"source":"Crossref","is-referenced-by-count":14,"title":["Fifth subtype of Kaposi sarcoma in HIV-negative MSM: a retrospective single-arm cohort study from a tertiary care center in NYC from 2000 to 2022"],"prefix":"10.1093","volume":"30","author":[{"given":"Ayana E","family":"Morales","sequence":"first","affiliation":[{"name":"Department of Medicine, Weill Cornell Medicine , New York, NY ,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gabrielle","family":"Benson","sequence":"additional","affiliation":[{"name":"Department of Medicine, Memorial Sloan Kettering Cancer Center , New York, NY ,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephanie","family":"Glavan","sequence":"additional","affiliation":[{"name":"Department of Medicine, Memorial Sloan Kettering Cancer Center , New York, NY ,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rosemary","family":"Giuliano","sequence":"additional","affiliation":[{"name":"Department of Medicine, Memorial Sloan Kettering Cancer Center , New York, NY ,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark A","family":"Dickson","sequence":"additional","affiliation":[{"name":"Department of Medicine, Weill Cornell Medicine , New York, NY ,","place":["United States"]},{"name":"Department of Medicine, Memorial Sloan Kettering Cancer Center , New York, NY ,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2025,3,13]]},"reference":[{"key":"2025031310475942100_CIT0001","doi-asserted-by":"crossref","first-page":"1865","DOI":"10.1126\/science.7997879","article-title":"Identification of herpesvirus-like DNA sequences in AIDS-associated Kaposi\u2019s sarcoma","volume":"266","author":"Chang","year":"1994","journal-title":"Science"},{"key":"2025031310475942100_CIT0002","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1038\/s41572-019-0060-9","article-title":"Kaposi sarcoma","volume":"5","author":"Cesarman","year":"2019","journal-title":"Nat Rev Dis Primers"},{"key":"2025031310475942100_CIT0003","doi-asserted-by":"publisher","first-page":"817","DOI":"10.1002\/(sici)1097-0215(19990909)82:6&lt;817::aid-ijc8&gt;3.0.co;2-7","article-title":"The role of immunosuppression and immune-activation in classic Kaposi\u2019s sarcoma","volume":"82","author":"Touloumi","year":"1999","journal-title":"Int J Cancer"},{"key":"2025031310475942100_CIT0004","doi-asserted-by":"publisher","first-page":"1521","DOI":"10.1038\/bjc.1998.717","article-title":"The geographical distribution of Kaposi\u2019s sarcoma and of lymphomas in Africa before the AIDS epidemic","volume":"78","author":"Cook-Mozaffari","year":"1998","journal-title":"Br J Cancer"},{"key":"2025031310475942100_CIT0005","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1093\/oxfordjournals.jncimonographs.a024250","article-title":"Kaposi\u2019s sarcoma in South Africa","volume":"2000","author":"Sitas","year":"2001","journal-title":"J Natl Cancer Inst Monogr"},{"key":"2025031310475942100_CIT0006","doi-asserted-by":"publisher","first-page":"1237","DOI":"10.1016\/0190-9622(90)70169-i","article-title":"Clinical manifestations of classical, endemic African, and epidemic AIDS-associated Kaposi\u2019s sarcoma","volume":"22","author":"Friedman-Kien","year":"1990","journal-title":"J Am Acad Dermatol"},{"key":"2025031310475942100_CIT0007","doi-asserted-by":"publisher","first-page":"872","DOI":"10.3390\/cancers15030872","article-title":"Endemic Kaposi\u2019s Sarcoma","volume":"15","author":"Zeinaty","year":"2023","journal-title":"Cancers (Basel)"},{"key":"2025031310475942100_CIT0008","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1186\/1750-9378-6-15","article-title":"Parasite infection is associated with Kaposi\u2019s sarcoma associated herpesvirus (KSHV) in Ugandan women","volume":"6","author":"Wakeham","year":"2011","journal-title":"Infect Agent Cancer"},{"key":"2025031310475942100_CIT0009","doi-asserted-by":"publisher","first-page":"948","DOI":"10.1056\/NEJM199804023381403","article-title":"Sexual transmission and the natural history of human herpesvirus 8 infection","volume":"338","author":"Martin","year":"1998","journal-title":"N Engl J Med"},{"key":"2025031310475942100_CIT0010","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1001\/jama.287.2.221","article-title":"Prevalence of Kaposi sarcoma-associated herpesvirus infection in homosexual men at beginning of and during the HIV epidemic","volume":"287","author":"Osmond","year":"2002","journal-title":"JAMA"},{"key":"2025031310475942100_CIT0011","doi-asserted-by":"publisher","first-page":"1267","DOI":"10.1111\/bjd.13102","article-title":"Kaposi sarcoma in HIV-negative men who have sex with men","volume":"171","author":"Rashidghamat","year":"2014","journal-title":"Br J Dermatol"},{"key":"2025031310475942100_CIT0012","doi-asserted-by":"publisher","first-page":"441","DOI":"10.1016\/j.jdcr.2017.04.012","article-title":"Nonepidemic Kaposi sarcoma: a recently proposed category","volume":"3","author":"Hinojosa","year":"2017","journal-title":"JAAD Case Rep"},{"key":"2025031310475942100_CIT0013","doi-asserted-by":"publisher","first-page":"1377","DOI":"10.1111\/jdv.14831","article-title":"A fifth subtype of Kaposi\u2019s sarcoma, classic Kaposi\u2019s sarcoma in men who have sex with men: a cohort study in Paris","volume":"32","author":"Denis","year":"2018","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"2025031310475942100_CIT0014","doi-asserted-by":"publisher","first-page":"538","DOI":"10.1111\/ijd.14080","article-title":"Epidemiology of Kaposi sarcoma: review and description of the nonepidemic variant","volume":"58","author":"Vangipuram","year":"2019","journal-title":"Int J Dermatol"},{"key":"2025031310475942100_CIT0015","doi-asserted-by":"publisher","first-page":"1163","DOI":"10.1097\/QAD.0b013e3283031a8a","article-title":"Kaposi\u2019s sarcoma in HIV-negative men having sex with men","volume":"22","author":"Lanternier","year":"2008","journal-title":"AIDS"},{"key":"2025031310475942100_CIT0016","doi-asserted-by":"publisher","first-page":"673","DOI":"10.1093\/aje\/145.8.673","article-title":"Risk of Kaposi\u2019s","volume":"145","author":"Grulich","year":"1997","journal-title":"Am J Epidemiol"},{"key":"2025031310475942100_CIT0017"},{"key":"2025031310475942100_CIT0018","doi-asserted-by":"publisher","first-page":"2159","DOI":"10.1007\/s00403-023-02552-2","article-title":"A description of Kaposi sarcoma risk factors and outcomes in HIV-positive and HIV-negative patients at a tertiary care medical center from 2005 to 2020","volume":"315","author":"Libson","year":"2023","journal-title":"Arch Dermatol Res"},{"key":"2025031310475942100_CIT0019","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1111\/j.1524-4725.2008.34397.x","article-title":"Treatment of classic Kaposi\u2019s sarcoma with topical imiquimod","volume":"35","author":"Goiriz","year":"2009","journal-title":"Dermatol Surg"},{"key":"2025031310475942100_CIT0020","doi-asserted-by":"publisher","first-page":"542","DOI":"10.1001\/archderm.138.4.542","article-title":"Topical 0.1% alitretinoin gel for classic Kaposi sarcoma","volume":"138","author":"Morganroth","year":"2002","journal-title":"Arch Dermatol"},{"key":"2025031310475942100_CIT0021","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1111\/dth.12381","article-title":"Classic Kaposi\u2019s sarcoma treated with topical 0.5% timolol gel","volume":"29","author":"Alc\u00e1ntara-Reifs","year":"2016","journal-title":"Dermatol Ther"},{"key":"2025031310475942100_CIT0022","doi-asserted-by":"publisher","first-page":"e107","DOI":"10.1002\/ski2.107","article-title":"Topical treatments for Kaposi sarcoma: A systematic review","volume":"2","author":"Htet","year":"2022","journal-title":"Skin Health Dis"},{"key":"2025031310475942100_CIT0023","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1200\/JCO.2013.51.6757","article-title":"Prospective stage-stratified approach to AIDS-related Kaposi\u2019s sarcoma","volume":"32","author":"Bower","year":"2014","journal-title":"J Clin Oncol"},{"key":"2025031310475942100_CIT0024","doi-asserted-by":"publisher","first-page":"2445","DOI":"10.1200\/JCO.1998.16.7.2445","article-title":"Pegylated-liposomal doxorubicin versus doxorubicin, bleomycin, and vincristine in the treatment of AIDS-related Kaposi\u2019s sarcoma: results of a randomized phase III clinical trial","volume":"16","author":"Northfelt","year":"1998","journal-title":"J Clin Oncol"},{"key":"2025031310475942100_CIT0025","doi-asserted-by":"publisher","first-page":"410","DOI":"10.1086\/589865","article-title":"Long-term prognosis of HIV-infected patients with Kaposi sarcoma treated with pegylated liposomal doxorubicin","volume":"47","author":"Mart\u00edn-Carbonero","year":"2008","journal-title":"Clin Infect Dis"},{"key":"2025031310475942100_CIT0026","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1002\/cncr.10634","article-title":"Multicenter trial of low-dose paclitaxel in patients with advanced AIDS-related Kaposi sarcoma","volume":"95","author":"Tulpule","year":"2002","journal-title":"Cancer"},{"key":"2025031310475942100_CIT0027","doi-asserted-by":"publisher","first-page":"840","DOI":"10.1158\/1078-0432.CCR-21-3364","article-title":"Safety, activity, and long-term outcomes of pomalidomide in the treatment of Kaposi sarcoma among individuals with or without HIV infection","volume":"28","author":"Ramaswami","year":"2022","journal-title":"Clin Cancer Res"},{"key":"2025031310475942100_CIT0028","doi-asserted-by":"publisher","first-page":"730","DOI":"10.1093\/cid\/civ996","article-title":"Clinical Features and Outcomes of Patients With Symptomatic Kaposi Sarcoma Herpesvirus (KSHV)-associated inflammation: prospective characterization of KSHV Inflammatory Cytokine Syndrome (KICS)","volume":"62","author":"Polizzotto","year":"2016","journal-title":"Clin Infect Dis"},{"key":"2025031310475942100_CIT0029","doi-asserted-by":"publisher","first-page":"1260","DOI":"10.2105\/AJPH.2018.304560","article-title":"Cancers disproportionately affecting the New York State Transgender Population, 1979\u20132016","volume":"108","author":"Hutchison","year":"2018","journal-title":"Am J Public Health"},{"key":"2025031310475942100_CIT0030","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1016\/j.hoc.2017.09.007","article-title":"Treatment of Kaposi sarcoma herpesvirus-associated multicentric castleman disease","volume":"32","author":"Lurain","year":"2018","journal-title":"Hematol Oncol Clin North Am"},{"key":"2025031310475942100_CIT0031","doi-asserted-by":"publisher","first-page":"2481","DOI":"10.1200\/JCO.2010.34.1909","article-title":"Clinical features and outcome in HIV-associated multicentric Castleman\u2019s disease","volume":"29","author":"Bower","year":"2011","journal-title":"J Clin Oncol"},{"key":"2025031310475942100_CIT0032","doi-asserted-by":"publisher","first-page":"1387","DOI":"10.1182\/blood-2007-03-080648","article-title":"Multicentric Castleman disease is associated with polyfunctional effector memory HHV-8-specific CD8+ T cells","volume":"111","author":"Guihot","year":"2008","journal-title":"Blood"}],"container-title":["The Oncologist"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/30\/3\/oyaf024\/62398447\/oyaf024.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/30\/3\/oyaf024\/62398447\/oyaf024.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,13]],"date-time":"2025-03-13T06:48:16Z","timestamp":1741848496000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/oncolo\/article\/doi\/10.1093\/oncolo\/oyaf024\/8074795"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3]]},"references-count":32,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2025,3,10]]}},"URL":"https:\/\/doi.org\/10.1093\/oncolo\/oyaf024","relation":{},"ISSN":["1083-7159","1549-490X"],"issn-type":[{"value":"1083-7159","type":"print"},{"value":"1549-490X","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,3]]},"published":{"date-parts":[[2025,3]]},"article-number":"oyaf024"}}